.png?width=700&name=New-ATE-Logo2019%20(1).png)
J.Media™:
Delivering a Perfusion Medium for
High Biotherapeutic Productivity and Robust
Scalability in CHO Cell Culture Platforms
Presenters:
Arnav Deshpande Senior Scientist II,
Just-Evotec Biologics
Arnav Deshpande is a senior scientist in the media development team at Just-Evotec Biologics, based in Seattle. He earned his doctoral degree in chemical engineering from Purdue University in 2022, where he engineered microbes to overproduce aromatic amino acids. His interest lies in characterizing cell metabolism using advanced characterization techniques. At Just-Evotec Biologics, his focus is on using high throughput, automated experimental workflows that are informed by data driven in-silico approaches to enable iterative CHO cell culture media development. Prior to this, he worked at a US Department of Energy National Lab where he characterized photosynthetic metabolism using isotopically labeled substrates and metabolomics towards development of sustainable energy solutions.
Matthew StebbinsMedia Development Group Lead,
Process and Product Development,
Just-Evotec Biologics
Matthew Stebbins is a principal scientist leading Just-Evotec Biologics’ media development and supply organization. In this role, he drives innovation in perfusion cell culture media design to support early- and late-stage process development programs, enabling scalable and cost-efficient biologics manufacturing. Matthew also spearheads technology development initiatives focused on optimizing media for high-intensity perfusion processes, advancing next-generation bioprocessing strategies.
He earned his doctoral in chemical engineering from the University of Wisconsin–Madison in 2017, where his research centered on tissue engineering and in vitro blood-brain barrier models for pharmaceutical development applications. This foundation in complex biological systems informs his approach to designing robust, high-performance perfusion media solutions for therapeutic protein production.
Prior to joining Just-Evotec Biologics, Matthew led end-to-end process development for viral vector raw materials in first-in-human cell and gene therapy programs at Bristol Myers Squibb. His experience spans upstream process development, raw material characterization, and cross-functional collaboration to accelerate timelines for cell and cell-derived therapies.
Matthew is passionate about leveraging data-driven approaches and systems-level thinking to improve bioprocess efficiency and reliability. His leadership in media development continues to shape strategies that reduce manufacturing costs and enhance flexibility for global biologics supply.
